Changing Business Models: The CFO’s Role When Pivoting for Success
By Nancy Hargreaves
As a CEO, when a board member or investor questions the feasibility of your company’s business model, you might be tempted to counter with the pat response “if it ain’t broke, don’t fix it”. But what if your business model IS broken? What should you do then? I work frequently…Read More
Read MoreRaising Capital in Life Sciences in 2022-2023: What Works?
By Greg Curhan
Raising money in the capital markets for a biopharma or life sciences company over the last few years has been quite a roller coaster ride. Funding among U.S. biotech startups reached a record high of $77 billion in 2021 (Crunchbase), as investors were attracted to expanding opportunities in genetics, therapeutics…Read More
Read MoreFundraising Choices in Life Sciences: What, When & Why?
By Linda Rubinstein
This article is the second in a two-part series about fundraising strategies for life science companies. In our last article, A Menu of Financing Alternatives for Life Science Companies, we looked at the continuum of choices available to life science companies who are actively engaged in fundraising to power up…Read More
Read MoreA Menu of Financing Alternatives for Life Science Companies
By Linda Rubinstein
This article is the first in a two-part series about fundraising strategies for life science companies. A Menu of Financing Alternatives for Life Science Companies Fundraising Choices in Life Sciences: What, When & Why? Life science companies, from emerging to evolved, therapeutics to diagnostics, solo or partnered, are constantly fundraising….Read More
Read More